About GLS Pharma
GLS Pharma is a Healthcare company based in Delhi (India) founded in 2004, and was acquired by Aurobindo Pharma in June 2022. Oncology APIs and anti-cancer products are manufactured. The company has 116 employees. Its Indian entity Gls Pharma Limited reported revenue of ₹36.08 Cr. Its focus areas include Traditional Pharmaceuticals, Generics, Therapeutic Areas and Oncology.
Company details
Founded in 2004 in Delhi, India, operations in the oncology pharmaceutical sector are conducted by GLS Pharma. Active pharmaceutical ingredients and finished formulations for solid and hematological malignancies are produced, along with supportive care therapies. Stringent quality standards are followed in manufacturing processes. Backward integration is utilized to manage costs while quality is preserved.
- Headquarters Delhi, India
- Employees 116
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Website glspharma.com
- Social LinkedIn X Facebook
- Acquired by Aurobindo Pharma (Jun 2022)
- Legal Name Gls Pharma Limited
- Date of Incorporation 01 Sep, 2004
- Jurisdiction Hyderabad, Telangana, India
- Annual Revenue₹36.08 Cr
FY 2023 · +13862% YoY
- Net Profit₹1.90 Cr
FY 2023 · 5% margin
- EBITDA₹5.27 Cr
FY 2023 · 15% margin
- Investors
- Employee Count116
- Acquired byAurobindo Pharma
(Jun 2022)
Associated legal entities of GLS Pharma
GLS Pharma operates through Gls Pharma Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2023) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Gls Pharma Limited CIN U24239TS2004PLC184306 | Active | 01 Sep 2004 | Hyderabad, Telangana | ₹36.1 Cr | 116 | 3 | View details |
Investors in GLS Pharma
GLS Pharma has secured backing from 1 investor. Prominent investors backing the company include Aurobindo Pharma.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Generic biocatalytic solutions are provided for pharmaceutical applications. | 1986 | aurobindo.com | Hyderabad, India |
Investor details for GLS Pharma
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Board of directors of Gls Pharma Limited (GLS Pharma)
Gls Pharma Limited is the primary company behind GLS Pharma. The board of Gls Pharma Limited currently have 3 directors; the longest-serving is Srinivasa Ramachandra Rao Ilapakurthy, appointed in 2023. 19 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Srinivasa Ramachandra Rao Ilapakurthy DIN 07878237 | Director | 15 Dec 2023 | 2 yrs 10 mo | Gls Pharma Limited |
| Ravikiran Namburi DIN 10780420 | Director | 20 Sep 2024 | 2 yrs 1 mo | Gls Pharma Limited |
| Pendem Harish Babu DIN 05221219 | Additional Director | 25 Oct 2025 | 11 mo | Gls Pharma Limited |
Financials of GLS Pharma
Figures of Gls Pharma Limited, the primary company behind GLS Pharma, for FY 2023. Revenue was ₹36.08 Cr (+13862% year on year). Net profit was ₹1.90 Cr (5% margin). EBITDA was ₹5.27 Cr (15% margin). Revenue has grown at a compounded annual rate of +11% over three years and +16% over five years.
- ₹36.08 CrRevenue · FY 2023 · +13862% YoY
- ₹1.90 CrNet profit · 5% margin
- ₹5.27 CrEBITDA · 15% margin
- ₹1.20 CrPaid-up capital
- 116Employees (provident fund records)
- +11%Revenue CAGR, 3 years
- +16%Revenue CAGR, 5 years
Balance sheet, profit and loss, cash flow and ratios of Gls Pharma Limited are on its company page.
Detailed financial statements for GLS Pharma
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of GLS Pharma
2 dated milestones of GLS Pharma across 18 years, from founding to its latest funding, stage changes and deals.
- Founded GLS Pharma is founded.
- Exit Acquired by Aurobindo Pharma.
Web traffic of GLS Pharma
The website of GLS Pharma (glspharma.com) receives about 1.3K visits a month.
- Monthly visits1.3K
▲ 13.4% vs previous month
Top companies in Traditional Health & Nutrition
3 companies that operate in the same segment as GLS Pharma (Traditional Health & Nutrition) in India, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Oral solid drug delivery systems are manufactured and developed. | 1985 | Mumbai, Maharashtra, India | USD 42.49 M | USD 89.42 M | 962 | |
Generic, semi-solid, and liquid dosage forms are manufactured. | 1990 | Bengaluru, Karnataka, India | USD 508.93 M | 5,180 | ||
Specialty generic pharmaceuticals and APIs are manufactured and marketed. | 1983 | Mumbai, Maharashtra, India | USD 6.21 B | 25,870 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about GLS Pharma
GLS Pharma was founded in 2004.
GLS Pharma is headquartered in Delhi, India. It is registered at Delhi, Delhi, India.
GLS Pharma has 116 employees.
The primary company behind GLS Pharma, Gls Pharma Limited, reported revenue of ₹36.08 Cr for FY 2023, up 13862% year on year.
Founded in 2004 in Delhi, India, operations in the oncology pharmaceutical sector are conducted by GLS Pharma. Active pharmaceutical ingredients and finished formulations for solid and hematological malignancies are produced, along with supportive care therapies. Stringent quality standards are followed in manufacturing processes. Backward integration is utilized to manage costs while quality is preserved.
GLS Pharma has 1 investor. Key investors include Aurobindo Pharma.
GLS Pharma operates through Gls Pharma Limited.
Yes. GLS Pharma was acquired by Aurobindo Pharma in June 2022.
The legal entities of GLS Pharma currently have 3 directors, including Srinivasa Ramachandra Rao Ilapakurthy, Pendem Harish Babu, Ravikiran Namburi.